MM-102 TFA | CAS#1883545-52-5 | WDR5/MLL interaction inhibitor

MedKoo Cat#: 555880 | Name: MM-102 TFA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MM-102 is a Potent WDR5/MLL interaction inhibitor. The MM-102 compound prevents the interaction between mixed lineage leukemia 1 (MLL1) and WD Trp-Asp repeat domain 5 (WDR5) and results in the inhibition of MLL1 H3K4 histone methyltransferase (HMT) activity. Down-Regulation of H3K4me3 by MM-102 Facilitates Epigenetic Reprogramming of Porcine Somatic Cell Nuclear Transfer Embryos

Chemical Structure

MM-102 TFA

CAS#1883545-52-5 (TFA)

Theoretical Analysis

MedKoo Cat#: 555880

Name: MM-102 TFA

CAS#: 1883545-52-5 (TFA)

Chemical Formula: C37H50F5N7O6

Exact Mass:

Molecular Weight: 783.84

Elemental Analysis: C, 56.70; H, 6.43; F, 12.12; N, 12.51; O, 12.25

Price and Availability

Size	Price	Availability
25mg	USD 450.00	2 Weeks
50mg	USD 750.00	2 Weeks
100mg	USD 1,250.00	2 Weeks
200mg	USD 1,950.00	2 Weeks
500mg	USD 3,650.00	2 Weeks
1g	USD 4,650.00	2 Weeks
2g	USD 7,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1417329-24-8 (free base) 1883545-52-5 (TFA)

Synonym

MM-102 TFA; MM-102 trifluoroacetic acid; MM-102; MM 102; MM102;

IUPAC/Chemical Name

1-[[(2S)-5-[(Aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]-cyclopentanecarboxamide trifluoroacetate

InChi Key

ZRKTWBXVGMHWHM-YCBFMBTMSA-N

InChi Code

InChI=1S/C35H49F2N7O4.C2HF3O2/c1-5-34(6-2,43-29(45)22(3)4)31(47)41-27(10-9-21-40-33(38)39)30(46)44-35(19-7-8-20-35)32(48)42-28(23-11-15-25(36)16-12-23)24-13-17-26(37)18-14-24;3-2(4,5)1(6)7/h11-18,22,27-28H,5-10,19-21H2,1-4H3,(H,41,47)(H,42,48)(H,43,45)(H,44,46)(H4,38,39,40);(H,6,7)/t27-;/m0./s1

SMILES Code

O=C(C1(NC([C@@H](NC(C(NC(C(C)C)=O)(CC)CC)=O)CCCNC(N)=N)=O)CCCC1)NC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3.O=C(O)C(F)(F)F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

MM-102 TFA (HMTase Inhibitor IX TFA) is a potent WDR5/MLL interaction inhibitor.

In vitro activity:

Evaluation of one such peptidomimetic, MM-102, in bone marrow cells transduced with MLL1-AF9 fusion construct shows that the compound effectively decreases the expression of HoxA9 and Meis-1, two critical MLL1 target genes in MLL1 fusion protein mediated leukemogenesis. MM-102 also specifically inhibits cell growth and induces apoptosis in leukemia cells harboring MLL1 fusion proteins. Reference: J Am Chem Soc. 2013 Jan 16;135(2):669-82. https://pubmed.ncbi.nlm.nih.gov/23210835/

In vivo activity:

This study demonstrates that MLL1, WDR5, and trimethylated H3K4 (H3K4me3) were upregulated in renal tubular cells of cisplatin-induced AKI in mice, along with increased phosphorylation of p53 and decreased expression of E-cadherin. Administration of MM102, a selective MLL1/WDR5 complex inhibitor, improved renal function and attenuated tubular injury and apoptosis, while repressing MLL1, WDR5, and H3K4me3, dephosphorylating p53 and preserving E-cadherin. Reference: Cell Death Dis. 2022 Sep 6;13(9):770. https://pubmed.ncbi.nlm.nih.gov/36068197/

	Solvent	mg/mL	mM	comments
Solubility
	DMSO	83.5	106.51

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 783.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Xiong Y, Wang Y, Ma L, Zhang Y, Qu X, Huang L, Wen X, Liu H, Zhang M, Zhang Y. Mixed-lineage leukaemia 1 contributes to endometrial stromal cells progesterone responsiveness during decidualization. J Cell Mol Med. 2021 Jan;25(1):297-308. doi: 10.1111/jcmm.16030. Epub 2020 Nov 17. PMID: 33201593; PMCID: PMC7810960. 2. Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J Am Chem Soc. 2013 Jan 16;135(2):669-82. doi: 10.1021/ja306028q. Epub 2012 Dec 27. PMID: 23210835; PMCID: PMC5180416. 3. Zhang C, Guan Y, Zou J, Yang X, Bayliss G, Zhuang S. Histone methyltransferase MLL1 drives renal tubular cell apoptosis by p53-dependent repression of E-cadherin during cisplatin-induced acute kidney injury. Cell Death Dis. 2022 Sep 6;13(9):770. doi: 10.1038/s41419-022-05104-0. PMID: 36068197; PMCID: PMC9448773. 4. Sun F, Mo L, Lan Y, Lu Q, Wu N, Song H. WDR5 drives the development of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition and cancer-associated fibroblasts formation. Pathol Res Pract. 2022 Aug 17;238:154076. doi: 10.1016/j.prp.2022.154076. Epub ahead of print. PMID: 36055087.

In vitro protocol:

In vivo protocol:

1. Zhang C, Guan Y, Zou J, Yang X, Bayliss G, Zhuang S. Histone methyltransferase MLL1 drives renal tubular cell apoptosis by p53-dependent repression of E-cadherin during cisplatin-induced acute kidney injury. Cell Death Dis. 2022 Sep 6;13(9):770. doi: 10.1038/s41419-022-05104-0. PMID: 36068197; PMCID: PMC9448773. 2. Sun F, Mo L, Lan Y, Lu Q, Wu N, Song H. WDR5 drives the development of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition and cancer-associated fibroblasts formation. Pathol Res Pract. 2022 Aug 17;238:154076. doi: 10.1016/j.prp.2022.154076. Epub ahead of print. PMID: 36055087.

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message Sent On: Wed Nov 04 11:48:53 2020 Search: MM102 20 selected items PubMed Results Items 1-20 of 20 (Display the 20 citations in PubMed) 1: Han X, Xiang J, Li C, Wang J, Wang C, Zhang Y, Li Z, Lu Z, Yue Y, Li X. MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro- fertilized embryos. Theriogenology. 2020 Apr 1;146:58-70. doi: 10.1016/j.theriogenology.2020.01.051. Epub 2020 Jan 29. PMID: 32059151. 2: Shimoda H, Doi S, Nakashima A, Sasaki K, Doi T, Masaki T. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16INK4a. Kidney Int. 2019 Nov;96(5):1162-1175. doi: 10.1016/j.kint.2019.06.021. Epub 2019 Aug 1. PMID: 31570196. 3: Zhang Z, Zhai Y, Ma X, Zhang S, An X, Yu H, Li Z. Down-Regulation of H3K4me3 by MM-102 Facilitates Epigenetic Reprogramming of Porcine Somatic Cell Nuclear Transfer Embryos. Cell Physiol Biochem. 2018;45(4):1529-1540. doi: 10.1159/000487579. Epub 2018 Feb 16. PMID: 29466785. 4: Weirich S, Kudithipudi S, Jeltsch A. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex. Mol Oncol. 2017 Apr;11(4):373-387. doi: 10.1002/1878-0261.12041. Epub 2017 Mar 10. PMID: 28182322; PMCID: PMC5527479. 5: Cai M, Bompada P, Atac D, Laakso M, Groop L, De Marinis Y. Epigenetic regulation of glucose-stimulated osteopontin (OPN) expression in diabetic kidney. Biochem Biophys Res Commun. 2016 Jan 1;469(1):108-113. doi: 10.1016/j.bbrc.2015.11.079. Epub 2015 Nov 22. PMID: 26592666. 6: Kim DS, Rashsuren O, Kim EK. Conversion coefficients for the estimation of effective dose in cone-beam CT. Imaging Sci Dent. 2014 Mar;44(1):21-9. doi: 10.5624/isd.2014.44.1.21. Epub 2014 Mar 19. Erratum in: Imaging Sci Dent. 2014 Sep;44(3):255-6. PMID: 24701455; PMCID: PMC3972402. 7: Karatas H, Townsend EC, Cao F, Chen Y, Bernard D, Liu L, Lei M, Dou Y, Wang S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein- protein interaction. J Am Chem Soc. 2013 Jan 16;135(2):669-82. doi: 10.1021/ja306028q. Epub 2012 Dec 27. PMID: 23210835; PMCID: PMC5180416. 8: Ashizawa T, Shimizu M, Gomi K, Okabe M. Antitumor activity of KW-2170, a novel pyrazoloacridone derivative. Anticancer Drugs. 1998 Mar;9(3):263-71. doi: 10.1097/00001813-199803000-00009. PMID: 9625437. 9: Maru M, Haraguchi M, Higashi H, Kato S, Kurimura T, Naiki M, Wakamiya N. Anti-tumor activity of ceramides and glycosphingolipids in a murine tumor system. Int J Cancer. 1993 Feb 20;53(4):645-50. doi: 10.1002/ijc.2910530420. PMID: 8436438. 10: Matsunaga K, Morita I, Iijima H, Endo H, Oguchi Y, Yoshimura M, Fujii T, Yoshikumi C, Nomoto K. Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts. J Clin Lab Immunol. 1990 Mar;31(3):127-36. PMID: 1966997. 11: Shiio T, Ohishi K, Tsuchiya Y, Niitsu I, Hayashibara H, Yoshihama T, Moriyuki H. [Combined use of lentinan with X-ray therapy in an experimental mouse tumor system (Part 2). Combined effect on the MM102 syngeneic tumor]. Gan To Kagaku Ryoho. 1988 Mar;15(3):475-9. Japanese. PMID: 3348633. 12: Yoshimoto R, Kondoh N, Isawa M, Hamuro J. Plant lectin, ATF1011, on the tumor cell surface augments tumor-specific immunity through activation of T cells specific for the lectin. Cancer Immunol Immunother. 1987;25(1):25-30. doi: 10.1007/BF00199297. PMID: 3496156. 13: Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C, Nomoto K. [Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors]. Gan To Kagaku Ryoho. 1986 Dec;13(12):3461-7. Japanese. PMID: 3789757. 14: Kawase I, Komuta K, Ogura T, Fujiwara H, Hamaoka T, Kishimoto S. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies. Cancer Res. 1985 Apr;45(4):1663-8. PMID: 3978634. 15: Toge T, Hamamoto S, Nakane H, Seto Y, Itagaki E, Hattori T. The enhancement of tumor cell susceptibility to macrophage binding and cytolysis by p-aminobenzoic acid-N-xyloside sodium salt (K-247). Int J Immunopharmacol. 1984;6(1):55-9. doi: 10.1016/0192-0561(84)90035-3. PMID: 6609891. 16: Kinouchi T, Fujiwara H, Hamaoka T. Expression of differentiation antigens cross-reactive with Ly-6.2 alloantigens on MM102 mouse mammary tumor cells. Gan. 1982 Oct;73(5):758-65. PMID: 6984683. 17: Fujiwara H, Aoki H, Tsuchida T, Hamaoka T. Immunologic characterization of tumor-associated transplantation antigens on MM102 mammary tumor eliciting preferentially helper T cell activity. J Immunol. 1978 Oct;121(4):1591-5. PMID: 308971. 18: Shimizu F, Arakawa M. Antitumor activity of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride in a variety of experimental tumors. Gan. 1978 Aug;69(4):545-8. PMID: 710804. 19: Fujiwara H, Hamaoka T, Teshima K, Aoki H, Kitagawa M. Preferential generation of killer or helper T-lymphocyte activity directed to the tumour- associated transplantation antigens. Immunology. 1976 Aug;31(2):239-48. PMID: 1085283; PMCID: PMC1445109. 20: Cyong J, Okada H. Histochemical studies on fatty acid in lymphocyte-mediated immune reaction. Immunology. 1976 May;30(5):763-7. PMID: 776819; PMCID: PMC1445032.